Palonosetron

Palonosetron structure

Palonosetron metabolites

Palonosetron is a 5-HT3 receptor antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) and also for postoperative nausea and vomiting (PONV). It is a second-generation 5-HT3 receptor antagonist with a strong affinity for the receptor and a longer half-life than the first-generation medications, making it particularly effective in preventing delayed nausea and vomiting associated with chemotherapy.

Mechanism of Action

Palonosetron works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting, at the 5-HT3 receptors located in the brain and in the upper gastrointestinal tract. This action prevents nausea and vomiting triggered by chemotherapy or surgery. Unlike its predecessors, palonosetron has a unique binding profile, with allosteric binding and positive cooperativity, which may contribute to its prolonged effect.

Clinical Use

Chemotherapy-Induced Nausea and Vomiting (CINV)

Palonosetron is approved for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy regimens. It is often used in combination with other antiemetic agents to enhance efficacy.

Postoperative Nausea and Vomiting (PONV)

It is also approved for the prevention of PONV for up to 24 hours following surgery. Palonosetron can be administered before surgery to prevent nausea and vomiting in the postoperative period.

Administration

Palonosetron is available in both intravenous and oral formulations, allowing for flexibility in administration based on the patient's needs and the specific clinical scenario. The intravenous form is typically used for CINV, while the oral form can be used for both CINV and PONV.

Side Effects

The most common side effects of palonosetron include headache, constipation, and fatigue. These side effects are generally mild and transient. As with all medications, allergic reactions can occur but are rare.

Comparison with Other Antiemetics

Palonosetron's longer half-life and unique mechanism of action provide it with some advantages over first-generation 5-HT3 receptor antagonists, such as ondansetron and granisetron. Studies have shown that palonosetron is more effective in preventing delayed nausea and vomiting, a significant concern for patients undergoing chemotherapy.

Conclusion

Palonosetron represents an important advancement in the management of CINV and PONV. Its unique pharmacological properties make it a valuable option for patients undergoing chemotherapy and surgery, helping to improve their quality of life during these challenging times.